https://www.ilfattoquotidiano.it
CellPly, an Italian company founded by Professor Roberto Guerrieri and Ing. Massimo Bocchi, developed an innovative platform to measure the in vitro effect of therapies, before their use in the clinical research. The platform is capable to predict the response of patients with leukemia to different types of therapies, in a standardized and automated manner. The device innovation consists in live cell analysis of efficacy associated with the tested therapies. Thanks to this technology, is possible to isolate cancer and immune cells, collected directly from patients. The wider use of this platform could be helpful to treat other kinds of disease, like COVID-19.